Not every peptide carries the same Google Ads risk. Here's how BPC-157, TB-500, and retatrutide compare, and how to structure a multi-compound account around it.
Not every peptide carries the same Google Ads risk. Brands running multi-compound catalogs often apply one compliance standard across the board — usually tuned to whichever compound is strictest — which either over-restricts lower-risk products or, more dangerously, under-restricts higher-risk ones. Understanding how BPC-157, TB-500, and retatrutide differ in review posture helps you allocate compliance effort where it actually matters.
BPC-157 has the longest advertising history of the three, which cuts both ways — Google's reviewers are highly familiar with common non-compliant patterns for this compound specifically, so generic research-use framing that might pass for a newer compound gets held to a stricter, more experienced standard here.
TB-500 sits in the same LegitScript-monitored bracket as BPC-157 but with a shorter advertising history, meaning reviewers apply the closest comparable standard (usually BPC-157's) by default. That makes TB-500 campaigns moderately unpredictable — treat it with BPC-157-level caution even though enforcement patterns are less mature.
Retatrutide's GLP-1 classification puts it under a different, currently faster-moving policy track than the two research peptides above (see our dedicated retatrutide compliance guide for the full breakdown). The practical difference: BPC-157 and TB-500 risk is largely stable and well-mapped; retatrutide risk is still shifting month to month.
Multi-compound account structure was a core part of scaling one peptide brand from $0 to $260K/month without a single cross-compound policy flag.
Compound-level nuance is exactly the kind of detail a generalist agency misses. Get a free strategy session with Oney Studio.
Get a free 30-minute audit of your Google Ads or Meta Ads account. We’ll review compliance, structure, and growth opportunities — no strings attached.
Book a Free Audit